|
 |
|
|
|||
|
 |
|
Mar. 3, 2025 Source: Elanco news release GREENFIELD, Ind. -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year 2024 and provided initial guidance for both the first quarter and full year 2025. "Elanco delivered a strong finish to 2024, achieving our sixth consecutive quarter of organic constant currency revenue growth -- with the fourth quarter up 4% -- and building momentum as we head into 2025," said Jeff Simmons, President and CEO of Elanco Animal Health. "For the year we grew in both Pet Health and Farm Animal, in our top five product franchises, and in nine of our top 10 countries, all on an organic constant currency basis, demonstrating the broad-based strength of our diverse portfolio. We exceeded our innovation revenue target for 2024 and raised the goal for 2025, with six potential blockbuster products now launched and reinforcing our confidence in mid-single digit organic constant currency revenue growth this year. "We generated over half a billion dollars of operating cash flow in 2024, doubling from the prior year through working capital discipline. Employee engagement is at a four-year high and our teams are already off to a fast start in 2025, focused on delivering a successful year and creating long-term value." Full Year 2024 Financial Results: *Exceeded innovation revenue target at $461 million *Revenue of $4,439 million, flat to prior year on a reported basis and up 3% on an organic constant currency basis *Reported Net Income of $338 million, Adjusted Net Income of $452 million *Adjusted EBITDA of $910 million, or 20.5% of Revenue *Reported EPS of $0.68, Adjusted EPS of $0.91 *Net leverage ratio of 4.3x Adjusted EBITDA To read the entire report click here. Tweet |
|
|
|
|
|
|
|
|
|||||||||||||
